Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Bell Potter Healthcare Conference (November 2026)
11 slides from Optiscan Imaging's conference presentation, Nov 17, 2026
Slide 1: A validated imaging platform taking its own products to market
rsonal use only A validated imaging platform taking its own products to market Optiscan Imaging Limited ASX: OIL INVESTOR PRESENTATION
Slide 2: Important notice
Important notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) and approved for release by Regulatory statements the Board of Optiscan. Regulatory status statements are as at the date of this presentation. Submission and clearance timing for InVue and rsonal us
Slide 3: Investment highlights
Investment highlights From technology supplier to product company: two human FDA submissions filed, and manufacturing in place. rsonal use only 01 Proven technology, now sold under Optiscan's own name WHERE THE COMPANY STANDS TODAY The core sits inside two cleared partner-branded devices (Pentax, Ca
Slide 4: Proven by global majors, now going to market alone
Proven by global majors, now going to market alone Optiscan spent its formative years proving the technology inside Pentax and Carl Zeiss products. It now manufactures, has regulatory experience and has its own product in market. rsonal use only 1994 1997 2002 2007 2021 Jul 2026 Oct 2026 Founded in
Slide 5: The answer arrives after the decision
The answer arrives after the decision WHERE CONVENTIONAL PATHOLOGY LEAVES A GAP rsonal use only The surgeon needs to know whether the margin is clear while the patient is still open. The conventional answer leaves the theatre and takes days, after the surgery is complete. Resection Fixation Processi
Slide 6: How Optiscan works, and why it is hard to copy
How Optiscan works, and why it is hard to copy HOW IT WORKS H&E CLE rsonal use only 01 A probe contacts the tissue A miniaturised confocal probe images tissue where it is, in the body or freshly excised. The scanner sits at the tip, so resolution holds at the point of contact. Conventional H&E slide
Slide 7: Patient, hospital and surgeon all come out ahead
Patient, hospital and surgeon all come out ahead What a hospital value analysis committee will test. Only reviewed figures are shown; per-site outcomes follow once reference-site data is observed. rsonal use only $45-55 10–45 min 25–30% $5,000–7,000 per minute of US operating room time added under a
Slide 8: Why we are confident on FDA clearances
Why we are confident on FDA clearances Both devices were filed as 510(k)s in October 2026, seeking a general, tissue-agnostic imaging indication. Clearances are anticipated from October 2027, subject to FDA review. rsonal use only InVue SURGERY · FILED 5 OCT 2026 InForm PATHOLOGY · FILED 1 OCT 2026
Slide 9: Place the console, earn on every procedure
Place the console, earn on every procedure In the first years, consoles are placed to drive procedures and adoption. Revenue comes from the sheath and service, then capital sales or leasing, with software and AI on top once cleared. rsonal use only GROW INSTALLED BASE AND CONSUMABLES HARDWARE · PLAC
Slide 10: Milestones begin in 1H 2027, ahead of clearance
Milestones begin in 1H 2027, ahead of clearance Indicative sequence. Each milestone depends on FDA review, site agreements and execution; regulatory and commercial events are shown separately. rsonal use only LATE 2026 MID 2027 LATE 2027 EARLY 2028 MID 2028 LATE 2028 LATE 2029 Up to five US Authoris
Slide 11: Dr Camile Farah, CEO & Managing Director
rsonal use only Dr Camile Farah MBA, PhD, MAICD, FAIM, FLWA CEO & Managing Director Optiscan Imaging Ltd (ASX:OIL) ceo@optiscan.com /company/Optiscan www.optiscan.com
Optiscan Imaging — Bell Potter Healthcare Conference (November 2026) on 6ix